Japan-based pharmaceutical company Takeda has announced 5 December as the date of its...
Delaware Supreme Court allows Fresenius to abandon Akorn acquisition
The Delaware Supreme Court in the US has ruled that German health care company Fresenius could legally back out of its acquisition of US-based Akorn.
November’s top stories
Sobi has signed agreements to acquire the rights to AstraZeneca’s Synagis medicine in the US for an upfront payment of $1.5bn, and Takeda Pharmaceutical has received a conditional approval from the EC for the $62bn proposed acquisition of Irish biopharmaceutical company Shire. Pharmaceutical-technology.com wraps up key headlines from November 2018.
SUDA and Zelda partner to develop medical grade cannabinoid spray
Australia-based SUDA Pharmaceuticals and Zelda Therapeutics have signed a feasibility and option agreement to develop a medical grade cannabinoid oral spray.
Mereo BioPharma to merge with OncoMed Pharmaceuticals
British pharmaceutical company Mereo BioPharma Group has announced a proposal to merge with US-based drugmaker OncoMed Pharmaceuticals.
Janssen affiliate Cilag and Argenx sign deal for cancer therapy
Janssen Pharmaceutical affiliate Cilag International has signed a global collaboration and license agreement with Dutch biotechnology company Argenx for cusatuzumab (ARGX-110) therapeutic.
GSK to acquire cancer therapeutics firm Tesaro for $5.1bn
GlaxoSmithKline (GSK) has signed a merger agreement to buy US-based biopharmaceutical company Tesaro for an aggregate consideration of around $5.1bn in a cash-based transaction.
Pfizer secures Humira licence agreements with AbbVie
Pfizer has resolved licensing issues regarding its adalimumab biosimilar that was deemed too close to AbbVie’s Humira (adalimumab).
Roche subsidiary Genentech to acquire Jecure Therapeutics
Swiss firm Roche Group’s affiliate Genentech has agreed to acquire US biotechnology company Jecure Therapeutics to strengthen its position in the treatment of liver diseases.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.